![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Avita Medical Completes Sale of Respiratory Business for $2.5M
Avita Medical Completes Sale of Respiratory Business for $2.5M
![Avita-Medical-pic.jpg](https://www.fdanews.com/ext/resources/test/Device_Images4/Avita-Medical-pic.jpg?t=1578337135&width=430)
February 9, 2016
Avita Medical has completed the sale of its respiratory business to Medical Developments International for almost $2.5 million.
The divestment will allow Avita to concentrate exclusively on its core business of regenerative medicine and wound care, the company said.
Avita’s respiratory business included two products — Breath-A-Tech and Funhaler — which are both asthma spacers aimed at optimizing the use of medicinal puffers.
The products are marketed in pharmacies throughout Australia. — Jonathon Shacat
Upcoming Events
-
21Oct